We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
Healthcare and Pharmaceuticals industry

Global Biopharmaceutical and Biomedicine Market Size Share Forecast 2024




 

Impact Analysis of Covid-19

The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Biopharmaceuticals has emerged as one of the key segments with immense growth potential in the healthcare sector. Rising demand for effective treatment and rise in per capita healthcare expenditure has led to double digit revenue growth for industry players in the recent past. The industry offers lucrative growth opportunities, since most of these products still have low penetration rate. The market is expected to gain further traction, with evolving treatment archetypes and rapid technological innovation such as cell therapy and regenerative medicines.
Market Dynamics
Launches and approvals of novel biopharmaceutical and biomedicine products is expected to drastically drive growth of global biopharmaceutical and biomedicine market in the near future. For instance, in 2016, Sanofi S.A. received U.S. FDA approval for its Adlyxin ((lixisenatide) injection. Adlyxin is indicated to improve blood sugar levels among adults suffering from type 2 diabetes. In 2016, Johnson & Johnson received U.S. FDA approval for its Stelara (Ustekinumab), indicated for the treatment of adults suffering from moderately to severely active crohn's disease. In 2016, CSL Behring received U.S. FDA approval for its IDELVION, Coagulation Factor IX (Recombinant), Albumin Fusion Protein. IDELVION is indicated for the treatment of Hemophilia B among children and adults. In 2017, Nanostring Technologies, Inc. launched nCounter platform advances as well as new panels expanding the company's presence in immuno-oncology and 3D biology research. In 2015, Celltrion Healthcare Co., Ltd. launched its Remsima (infliximab), a biosimilar monoclonal antibody (mAb) in Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden, and the UK. Furthermore, increasing collaborations and acquisitions by major key players in market is also expected to create lucrative environment for growth of market. For instance, in 2016, Biocon Ltd., wholly owned subsidiary of Biocon SA, collaborated with Laboratorios PiSA S.A. de C.V—a Mexico-based company—for the co-development and commercialization of generic recombinant human insulin (rh-insulin) in the U.S. market. In 2016, AbbVie Inc. acquired all rights from Boehringer Ingelheim (BI) for Risankizumab (BI 655066). Risankizumab is an anti-IL-23 monoclonal biologic antibody for psoriasis. Company is also evaluating the product for other indications such as Crohn's disease, asthma, and psoriatic arthritis. Currently, it is in clinical phase 3.
Key features of the study:
• This report provides in-depth analysis of biopharmaceutical and biomedicine market and provides market size (US$ Billion) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017-2025), considering 2016 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global biopharmaceutical and biomedicine market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Amgen Inc., F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., Eli Lilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb, NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and Affimed N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global biopharmaceutical and biomedicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the biopharmaceutical and biomedicine market
Detailed Segmentation:
• Global Biopharmaceutical and Biomedicine Market, By Product Type :
o Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
o Nanomedicine
o Cell & Gene Therapy
o Bioinformatics
o Molecular Enzymes & Kits Market
• Global Biopharmaceutical and Biomedicine Market, By Application:
o Therapeutics
o Diagnostics
o Research and Development
• Global Biopharmaceutical and Biomedicine Market, By Geography:
o North America
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 Nanomedicine
 Cell & Gene Therapy
 Bioinformatics
 Molecular Enzymes & Kits Market
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 U.S.
 Canada
o Europe
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 Nanomedicine
 Cell & Gene Therapy
 Bioinformatics
 Molecular Enzymes & Kits Market
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 U.K.
 Germany
 Italy
 France
 Spain
 Russia
 Rest of Europe
o Asia Pacific
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 Nanomedicine
 Cell & Gene Therapy
 Bioinformatics
 Molecular Enzymes & Kits Market
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 China
 India
 Japan
 ASEAN
 Australia
 South Korea
 Rest of Asia Pacific
o Latin America
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 Brazil
 Mexico
 Argentina
 Rest of Latin America
o Middle East
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 GCC
 Israel
 Rest of Middle East
o Africa
 By Product Type :
 Biopharmaceutical
 Monoclonal Antibodies Market
 Vaccines
 Recombinant Human Insulin
 Human Growth Hormone
 Erythropoietin
 Interferon
 Colony Stimulating Factor
 Blood Factors
 Fusion Protein
 Others
 By Application:
 Therapeutics
 Diagnostics
 Research and Development
 By Country:
 Central Africa
 South Africa
 North Africa
• Company Profiles
o Amgen Inc.*
 Company Overview
 Product Portfolio
 Financial Performance
 Recent Developments
 Key Strategies
o F. Hoffmann-La Roche AG
o Novartis AG
o Johnson & Johnson
o Pfizer, Inc.
o Sanofi S.A.
o Eli Lilly and Company
o AbbVie Inc.
o Novo Nordisk A/S
o Bristol - Myers Squibb
o NanoString Technologies, Inc.
o Qiagen N.V.
o Celgene Corporation
o Affimed N.V.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
? Research Objectives
? Assumptions
? Abbreviations
2. Market Purview
? Report Description
? Market Definition and Scope
? Executive Summary
? Market Snippet, By Product Type
? Market Snippet, By Application
? Market Snippet, By Region
? Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
? Market Dynamics
? Drivers
? Restraints
? Market Opportunities
? PEST Analysis
? Pipeline Analysis
? Product Approval
? Product Launch
? Collaboration-Acquisition
? Porter's Five Forces Analysis
4. Global Biopharmaceutical and Biomedicine Market, By Product Type, 2015-2025 (US$ Bn)
? Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2016-2025
? Segment Trends
? Biopharmaceutical
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Segment Trends
? Monoclonal Antibodies Market
? Vaccines
? Recombinant Human Insulin
? Human Growth Hormone
? Erythropoietin
? Interferon
? Colony Stimulating Factor
? Blood Factors
? Fusion Protein
? Others
? Nanomedicine
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Cell & Gene Therapy
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Bioinformatics
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Molecular Enzymes & Kits Market
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
5. Global Biopharmaceutical and Biomedicine Market, By Application, 2015-2025 (US$ Bn)
? Introduction
? Market Share Analysis, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, 2016-2025
? Segment Trends
? Therapeutics
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Diagnostics
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
? Research and Development
? Introduction
? Market Size and Forecast, and Y-o-Y Growth, 2015-2025, (US$ Bn)
6. Global Biopharmaceutical and Biomedicine Market, By Region, 2015-2025 (US$ Bn)
? Introduction
? Market Share Analysis, By Region, 2016 and 2025 (%)
? Y-o-Y Growth Analysis, For Regions, 2016-2025
? North America
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? U.S.
? Canada
? Europe
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? U.K.
? Germany
? Italy
? France
? Spain
? Russia
? Rest of Europe
? Asia Pacific
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? China
? India
? Japan
? ASEAN
? Australia
? South Korea
? Rest of APAC
? Latin America
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? Brazil
? Mexico
? Argentina
? Rest of Latin America
? Africa
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? Central Africa
? South Africa
? North Africa
? Middle East
? Market Size and Forecast, By Product Type, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Application, 2015-2025 (US$ Bn)
? Market Size and Forecast, By Country, 2015-2025 (US$ Bn)
? GCC
? Israel
? Rest of Middle East
7. Competitive Landscape
? Heat Map Analysis
? Company Profiles
? Amgen Inc.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? F. Hoffmann-La Roche AG
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Novartis AG
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Johnson & Johnson
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Pfizer, Inc.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Sanofi S.A.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Eli Lilly and Company
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? AbbVie Inc.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Novo Nordisk A/S
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Bristol - Myers Squibb
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? NanoString Technologies, Inc.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Qiagen N.V.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Celgene Corporation
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
? Affimed N.V.
? Company Overview
? Product Portfolio
? Key Developments
? Financial Performance
? Strategies
8. Section
? References
? Research Methodology
? About us and Sales Contact
*Browse 45 market data tables and 42 figures on "Biopharmaceutical and Biomedicine Market - Global forecast to 2025".

 



Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Mn Units).
Market is segmented by Product Types, Drug Class, Indication, Applications, Services Types, End-users, Distribution channel, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, pipeline Analysis, incidence rate, epidemiology analysis, prevalence rate, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, export-import analysis, trade analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Get In Touch

In search of customized market research solution? We are here to help you. Contact us.